Curated News
By: NewsRamp Editorial Staff
September 12, 2025
Quantum BioPharma's Unbuzzd Hosts Investor Webinar on Alcohol Metabolism Beverage
TLDR
- Quantum BioPharma's licensee Unbuzzd Wellness offers investors a Reg D 506(c) opportunity to gain early access to a scientifically proven alcohol metabolism beverage.
- Unbuzzd Wellness will host an investor webinar on September 16, 2025, featuring clinical data review and sales acceleration strategies for their alcohol metabolism beverage.
- Unbuzzd's beverage technology accelerates alcohol metabolism and reduces hangover symptoms, potentially improving public health and safety related to alcohol consumption.
- Quantum BioPharma's spin-off Unbuzzd Wellness developed a beverage that scientifically accelerates alcohol metabolism and restores mental clarity.
Impact - Why it Matters
This news matters because it highlights advancements in biotech solutions for alcohol-related health issues, offering potential benefits for consumers seeking to mitigate hangover effects and improve mental clarity. For investors, it presents a unique opportunity in the growing wellness and biopharmaceutical sectors, with Quantum BioPharma's strategic ownership and royalty structure providing sustained revenue potential. The development of products like unbuzzd™ and Lucid-MS addresses significant unmet medical needs, potentially impacting public health and offering new investment avenues in innovative healthcare technologies.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, has announced that its licensee Unbuzzd Wellness will host an Investor Webinar on September 16, 2025. The event will feature key executives including CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David, who will discuss the current Reg D 506(c) investment opportunity, review clinical data, and outline strategies to accelerate sales of unbuzzd™, a scientifically proven beverage designed to accelerate alcohol metabolism and reduce hangover symptoms.
Quantum BioPharma retains significant ownership in Unbuzzd Wellness Inc., holding 20.11% as of March 31, 2025, and benefits from royalty payments of 7% of sales up to $250 million, after which it drops to 3% in perpetuity. The company also maintains full rights to develop similar products for pharmaceutical and medical uses. Through its subsidiary Lucid Psycheceuticals, Quantum is advancing Lucid-MS, a patented compound targeting myelin degradation in multiple sclerosis, while its strategic investments arm, FSD Strategic Investments Inc., manages a portfolio of property-secured loans. For more details, visit the full press release at https://ibn.fm/Xp5a2.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Unbuzzd Hosts Investor Webinar on Alcohol Metabolism Beverage
